Definition and Specifications of Sepsis-Pipeline Review, H2 2016

Sepsis-Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Sepsis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects.

To access full report with TOC, please visit Sepsis-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sepsis
- The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
- The report reviews latest news related to pipeline therapeutics for Sepsis

Reasons to buy

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Adrenomed AG Altor BioScience Corporation Am-Pharma B.V. Arch Biopartners, Inc. Aridis Pharmaceuticals LLC Asahi Kasei Pharma Corp. Astellas Pharma Inc. Batu Biologics, Inc. Biomedica Management Corporation Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Cell2B S.A. Chiesi Farmaceutici SpA Chiome Bioscience, Inc. Cilian AG Cognosci, Inc. Cytheris SA Endacea, Inc. Evec, Inc. Huons Co., Ltd. Immune Response BioPharma, Inc. Immunethep, SA ImmunNovative Developments SL InflaRx GmbH Inotrem S.A. Integrated BioTherapeutics, Inc. Lead Discovery Center GmbH Merck & Co., Inc. Navigen Pharmaceuticals, Inc. OncoImmune, Inc. Opsona Therapeutics Limited Orion Oyj ProThera Biologics, LLC. Ra Pharmaceuticals, Inc. Recce Pty Ltd Ribomic Inc. Shionogi & Co., Ltd. Silence Therapeutics Plc SK Biopharmaceuticals Co., Ltd. Stemedica Cell Technologies, Inc. Syntiron LLC TaiRx, Inc. Takeda Pharmaceutical Company Limited Therakind Limited Therashock, LLC TiGenix NV VBS Pharmaceuticals ViiV Healthcare Limited XImmune AB

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###